Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Jul 29, 2016 3:09pm

86 Views

Post# 25096800

RE:RE:RE:RE:RE:A checklist of concerns for management

Nicely articulated SanFran. Thanks!

I think the response to the hard work you and BDAZ and others says a lot about Mr Paradis and Don and RVX and will certainly hinder any confidence in investors.

It's very disappointing to say the least. I'm assuming Mr Paradis is a fairly junior person with little authority and with very limited communications and strategic capabilities.

Anyway, I should be waiting for other poster's responses but I had to react. Very sad indeed but it confirms what we all know about this company.

So I guess the hard work you have done has served to flush them out and that is valuable.

So the follow up, perhaps, becomes "what are they afraid of?".

Too bad. I'll read ahead for other insights.
Toinv

Bullboard Posts

Changing Europe’s dependency on HREE from China